Athira Pharma (ATHA) Stock Forecast, Price Target & Predictions
ATHA Stock Forecast
Athira Pharma stock forecast is as follows: an average price target of $18.00 (represents a 2631.00% upside from ATHA’s last price of $0.66) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
ATHA Price Target
The average price target for Athira Pharma (ATHA) is $18.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $33.00 to $3.00. This represents a potential 2631.00% upside from ATHA's last price of $0.66.
ATHA Analyst Ratings
According to 4 Wall Street analysts, Athira Pharma's rating consensus is 'Buy'. The analyst rating breakdown for ATHA stock is 0 'Strong Buy' (0.00%), 2 'Buy' (50.00%), 2 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Athira Pharma Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 22, 2022 | Andrew Tsai | Jefferies | $3.00 | $2.85 | 5.26% | 355.17% |
| Apr 21, 2022 | - | Berenberg Bank | $33.00 | $11.63 | 183.75% | 4906.83% |
The latest Athira Pharma stock forecast, released on Jun 22, 2022 by Andrew Tsai from Jefferies, set a price target of $3.00, which represents a 5.26% increase from the stock price at the time of the forecast ($2.85), and a 355.17% increase from ATHA last price ($0.66).
Athira Pharma Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.66 | $0.66 | $0.66 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Athira Pharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Athira Pharma's last price of $0.66. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 04, 2024 | Rodman & Renshaw | Buy | Neutral | Downgrade |
| Sep 04, 2024 | JMP Securities | Perform | Market Perform | Downgrade |
| Sep 04, 2024 | JMP Securities | Market Outperform | Perform | Downgrade |
| Sep 04, 2024 | BTIG | Neutral | Positive | Downgrade |
| Sep 03, 2024 | BTIG | - | Neutral | Downgrade |
| Aug 19, 2024 | Rodman & Renshaw | - | Buy | Initialise |
| Oct 17, 2022 | JMP Securities | - | Market Outperform | Upgrade |
| Jun 22, 2022 | Jefferies | - | Buy | Downgrade |
Athira Pharma's last stock rating was published by Rodman & Renshaw on Sep 04, 2024. The company Downgrade its ATHA rating from "Buy" to "Neutral".
Athira Pharma Financial Forecast
Athira Pharma Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | $100.00K |
| High Forecast | - | - | - | - | - | - | - | $100.00K |
| Low Forecast | - | - | - | - | - | - | - | $100.00K |
| # Analysts | - | - | - | - | - | - | - | 1 |
| Surprise % | - | - | - | - | - | - | - | - |
Athira Pharma's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ATHA's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Athira Pharma EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 |
| EBITDA | - | - | - | - | - | - | - | $-8.46M |
| Avg Forecast | - | - | - | - | - | - | - | $-17.44M |
| High Forecast | - | - | - | - | - | - | - | $-13.95M |
| Low Forecast | - | - | - | - | - | - | - | $-20.93M |
| Surprise % | - | - | - | - | - | - | - | 0.48% |
undefined analysts predict ATHA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Athira Pharma's previous annual EBITDA (undefined) of $NaN.
Athira Pharma Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 |
| Net Income | - | - | - | - | - | - | - | $-8.46M |
| Avg Forecast | $-8.09M | $-12.90M | $-12.52M | $-12.13M | $-17.46M | $-27.03M | $-28.29M | $-18.87M |
| High Forecast | $-8.09M | $-12.90M | $-12.52M | $-12.13M | $-17.46M | $-27.03M | $-28.29M | $-15.10M |
| Low Forecast | $-8.09M | $-12.90M | $-12.52M | $-12.13M | $-17.46M | $-27.03M | $-28.29M | $-22.65M |
| Surprise % | - | - | - | - | - | - | - | 0.45% |
Athira Pharma's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ATHA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Athira Pharma SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 |
| SG&A | - | - | - | - | - | - | - | $1.57M |
| Avg Forecast | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - |
Athira Pharma's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to ATHA last annual SG&A of $1.57M (Sep 20).
Athira Pharma EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 |
| EPS | - | - | - | - | - | - | - | $-1.12 |
| Avg Forecast | $-0.21 | $-0.34 | $-0.33 | $-0.32 | $-0.45 | $-0.70 | $-0.74 | $-0.25 |
| High Forecast | $-0.21 | $-0.34 | $-0.33 | $-0.32 | $-0.45 | $-0.70 | $-0.74 | $-0.25 |
| Low Forecast | $-0.21 | $-0.34 | $-0.33 | $-0.32 | $-0.45 | $-0.70 | $-0.74 | $-0.25 |
| Surprise % | - | - | - | - | - | - | - | 4.48% |
According to undefined Wall Street analysts, Athira Pharma's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ATHA previous annual EPS of $NaN (undefined).
Athira Pharma Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ATHA | Athira Pharma | $0.66 | $18.00 | 2627.27% | Buy |
| SPRO | Spero Therapeutics | $1.19 | $10.00 | 740.34% | Buy |
| CTMX | CytomX Therapeutics | $0.87 | $5.73 | 558.62% | Buy |
| TIL | Instil Bio | $24.76 | $78.25 | 216.03% | Hold |
| NUVB | Nuvation Bio | $2.70 | $6.75 | 150.00% | Buy |
| ASMB | Assembly Biosciences | $14.72 | $35.50 | 141.17% | Buy |
| NXTC | NextCure | $1.29 | $3.00 | 132.56% | Buy |
| ACHL | Achilles Therapeutics | $1.07 | $2.00 | 86.92% | Buy |